All the news Showing 10 of 11 articles from: New and experimental treatments for hepatitis BGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources NASVAC therapeutic vaccine may lead to functional cure of hepatitis B Liz Highleyman / 17 November 2020 NASVAC, an experimental therapeutic vaccine that targets two different hepatitis B virus (HBV) antigens, led to a reduction in hepatitis B surface antigen levels and several study participants achieved a functional cure after ... Gilead immune modulator has modest effect on hepatitis B surface antigen Keith Alcorn / 01 September 2020 Selgantolimod, a toll-like receptor agonist designed to enhance immune responses to hepatitis B virus, showed only modest effects on hepatitis B surface antigen levels in a phase 2 safety and efficacy study presented ... JNJ-3989 achieves sustained reductions in hepatitis B surface antigen Keith Alcorn / 29 August 2020 Johnson & Johnson’s short interfering RNA treatment for hepatitis B resulted in sustained reductions in hepatitis B surface antigen when combined with nucleoside analogue drugs, Professor Edward Gane of Auckland City Hospital, New ... GSK antisense agent for hepatitis B shows promise Keith Alcorn / 29 August 2020 An antisense agent, GSK-3228836, significantly reduced hepatitis B surface antigen levels in previously untreated people with chronic hepatitis B after three injections, an early phase trial reported this week at the Digital International ... Therapeutic hepatitis B vaccine may lead to functional cure Liz Highleyman / 13 November 2019 An experimental therapeutic vaccine called NASVAC, which targets two different hepatitis B virus (HBV) antigens, led to a reduction in hepatitis B surface antigen (HBsAg) levels, according to study presented this week ... Bulevirtide is a potential cure for hepatitis B and D Liz Highleyman / 16 April 2019 Bulevirtide, formerly known as Myrcludex B, led to suppression of hepatitis delta virus (HDV) and a functional cure of hepatitis B virus (HBV) in some people with both viruses when combined with pegylated ... Hepatitis B capsid inhibitors look promising in early studies Liz Highleyman / 18 April 2018 Two experimental drugs that interfere with assembly of the hepatitis B virus (HBV) capsid and prevent production of functional new virus demonstrated good safety and promising antiviral activity in early clinical trials, according ... GS-4774 therapeutic vaccine shows little efficacy in people with hepatitis B Liz Highleyman / 08 December 2016 An experimental immune-based therapy for chronic hepatitis B combined with tenofovir was safe and well tolerated but did not lead to greater reductions in hepatitis B surface antigen (HBsAg) than the antiviral alone, ... Tenofovir alafenamide approved for hepatitis B, works well with less effect on bones Liz Highleyman / 15 November 2016 Tenofovir alafenamide (TAF), a new lower-dose pro-drug, matches the older tenofovir disoproxil fumarate (TDF) for antiviral activity against hepatitis B virus (HBV) but causes less bone mineral loss, according to a report this ... Core inhibitor NVR 3-778 plus pegylated interferon inhibits hepatitis B activity Liz Highleyman / 05 May 2016 NVR 3-778, an experimental drug that interferes with hepatitis B virus (HBV) capsid assembly, led to reductions in HBV DNA, HBV RNA and hepatitis B 'e' antigen (HBeAg), showing greater activity when ... ← First12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds